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ABSTRACT
Objective. To describe differences in 
clinical presentation between men and 
women in a large group of patients 
with early (<3 years’ duration) system-
ic sclerosis (SSc) according to disease 
subsets.
Methods. A cross-sectional analysis of 
the prospective EULAR Scleroderma 
Trial and Research database (EUS-
TAR) was performed. Patients fulfilling 
preliminary ACR 1980 classification 
criteria for SSc, with less than 3 years 
from the first non-Raynaud’s symptom 
at first entry, were selected. A group of 
patients with less than 3 years from the 
first SSc symptom, including Raynaud’s 
phenomenon, was also analysed. SSc 
related variables, including antibodies, 
SSc subsets, disease activity and organ 
involvement were included. Descriptive 
and bivariate analyses were performed.
Results. A total of 1,027 patients were 
included, 90% Caucasian, 80% women, 
and 40% with diffuse cutaneous dis-
ease. In early stages of SSc, men showed 
more frequently than women active dis-
ease, diffuse cutaneous subset, anti-
Scl-70 antibodies, elevated acute phase 
reactants, muscular and pulmonary 
involvement. Differences between men 
and women were confirmed in the limit-
ed, but not in the diffuse SSc subset. The 
results were similar when 650 patients 
with less than three years from the first 
SSc symptom, including Raynaud’s phe-
nomenon, were analysed.
Conclusion. In early stages of SSc, 
men present signs and symptoms of 
more severe disease. In the limited dis-
ease subset, men might appear with 
clinical features and organ involve-
ment similar to those of the diffuse sub-
group. In clinical practice, the identifi-
cation of such differences might help to 
select the appropriate management for 
each particular patient.
Introduction
Systemic sclerosis (SSc) is a rare dis-
ease, with an estimated prevalence of 
8-30 cases per 100,000 inhabitants (1-
3) and a very low annual incidence, 
from 1 to 2.5 new cases per 100,000 
inhabitants (1, 4). SSc affects more 
frequently women than men, and is 
associated with significant morbidity, 
including pain, disability, depression, 
reduced quality of life, increased mor-
tality, and high costs (1, 2, 5-8).
SSc is also a complex disease, present-
ing different clinical patterns that may 
influence outcomes. These differences 
could be present both at the onset and/
or during the disease course. Thus, 
as in other chronic autoimmune dis-
eases, the study of factors that might 
modulate disease outcome is crucial. 
Among these factors, gender has been 
described to play a key role in the in-
cidence, severity and progression of 
autoimmune diseases (9). Such differ-
ences have been explained, at least in 
part, by genetic and hormonal factors, 
as well as by lifestyle patterns (10).
In SSc, male sex is associated with 
worse outcomes including survival 
(1, 2, 6, 11-14). In prevalent studies, 
men have been found to present more 
frequently diffuse cutaneous involve-
ment, anti-Scl-70 antibodies and se-
vere organ involvement, less frequent-
ly anti-centromere antibody (ACA), 
and a shorter time between the onset of 
Raynaud’s phenomenon and first non-
Raynaud’s symptom of the disease (15-
17). Nevertheless, the low number of 
men analysed in previous studies and 
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the clinical heterogeneity of the dis-
ease, make difficult the generalisation 
of these findings. Moreover, there is 
little information regarding to whether 
the effect of these factors might be al-
ready present at disease onset.
The EULAR Scleroderma Trials and 
Research (EUSTAR) group established 
a prospective multicentre SSc cohort to 
foster the awareness, understanding and 
research of SSc and its care and man-
agement throughout Europe (18). EUS-
TAR database provides a unique oppor-
tunity to study a large and representa-
tive number of SSc patients, facilitating 
the accuracy of a very well defined set 
of outcomes, including disease onset.
The aim of this study is to analyse in 
detail gender differences in clinical 
presentation early after disease on-
set, in an effort to contribute to the 
understanding of SSc clinical course 
and outcome. In clinical practice, this 
might also lead to improvements in the 
identification of cases, monitoring and 
decision making, in order to minimise 
SSc impact during the disease course. 
Methods
EUSTAR database
The EUSTAR database has been pre-
viously described (18). Briefly, the 
database was initiated in June 2004 
and documents a multinational (194 
centres), prospective and open SSc co-
hort. Participating centres seek ethics 
committee approval, followed by the 
entry of the Minimal Essential Data 
set (MEDS) for all consecutive con-
senting patients with SSc, including 
data on demographics, disease onset, 
clinical features and disease activity. 
The disease is considered active, ac-
cording to the SSc activity score pro-
posed by the European Scleroderma 
Study Group  (19), if the sum of the 
scores of detected items with their re-
spective weight (modified Rodnan skin 
score> 14, hand or fingers oedema, 
skin worsening, digital ischaemia/ne-
crosis, vascular worsening, arthritis, 
DLCO<80%, worsening of heart/lung 
disease, ESR>30, hypocomplementae-
mia) is ≥3 (19). Data are updated an-
nually. For the purpose of the present 
study, all patients included in the EUS-
TAR database until June 2008 (the time 
of data extraction for this analysis), 
fulfilling the preliminary ACR 1980 
classification criteria for SSc (20), and 
with less than 3 years from the first 
non-Raynaud’s SSc symptom at the 
first EUSTAR entry, were selected. The 
group of patients with less than 3 years 
from the first SSc symptom, including 
Raynaud’s phenomenon, was also stud-
ied. Very early subgroups, defined as 
disease duration of less than 12 months 
from the first non-Raynaud’s symptom 
or from the first SSc symptom, includ-
ing Raynaud’s phenomenon, respec-
tively, were analysed as well.
Variables
Baseline data of the first EUSTAR en-
try were analysed. All the variables in-
cluded in the analysis have been previ-
ously defined in EUSTAR (18). From 
EUSTAR MEDS, only objective vari-
ables, defined and measured by vali-
dated criteria, specific measurements 
or imaging techniques were considered. 
Subjective variables such as dyspnea, 
palpitations or muscular weakness were 
not analysed. Digestive symptoms (oe-
sophagus, stomach and gut symptoms), 
although subjective, were integrated 
into one variable (digestive involve-
ment) and analysed. The presence of 
Raynaud’s phenomenon and ANA 
positivity as dichotomised variables, 
were also excluded from the analy-
ses because they were present in more 
than 90% of the study sample, and their 
presence did not influence the results.
Finally, we analysed the following 
variables a) socio-demographic in-
cluding sex, age (at EUSTAR entry, at 
first non-Raynaud’s symptom, at first 
SSc symptom, including Raynaud’s); 
b) disease related variables: time 
between Raynaud’s and first non-
Raynaud symptom; disease duration, 
calculated from the onset of the first 
non-Raynaud’s symptom and also 
from the first SSc symptom, including 
Raynaud’s; SSc subsets as previously 
proposed (21): diffuse cutaneous sys-
temic sclerosis (dcSSc), and limited 
cutaneous systemic sclerosis (lcSSc), 
considering the disease course from 
the beginning, and being mutually ex-
clusive, that is, if a patient had ever 
diffuse cutaneous involvement he/she 
would be always considered dcSSc; 
positivity for anti-Scl70 and ACA an-
tibodies; mRSS (modified Rodnan skin 
score); disease activity - calculated as 
a composite score from MEDS features 
according to the preliminary index for 
SSc, proposed by the European Sclero-
derma Study Group, described above 
and detailed elsewhere(19) - ; elevation 
of acute phase reactants (ESR higher 
than 30 mm and/or CRP over normal 
values); vascular involvement includ-
ing ischaemic digital ulcers; joint in-
volvement defined as the presence of 
synovitis, joint contractures or tendon 
friction rubs; muscle involvement de-
fined as CK (creatine kinase) elevation; 
digestive involvement as previously 
defined; lung involvement including fi-
brosis (diagnosed by x-ray or thoracic 
computed tomography), lung restrictive 
defect, defined as Forced Vital Capac-
ity (FVC) below 80%, and DLCO (dif-
fusion capacity of the lung for carbon 
monoxide, % of predicted) level; cardi-
ac involvement, including the presence 
of conduction blocks in EKG, diastolic 
dysfunction, or left ventricular ejection 
fraction <55% in cardiac echocardiog-
raphy; elevated sPAP (estimated systol-
ic pulmonary artery pressure), defined 
as an estimated sPAP higher than 40 
mmHg in Doppler echocardiography; 
and renal crisis.
Statistical analysis
Quantitative variables were described 
by means ± standard deviations (SD) 
and qualitative variables with frequen-
cies and percentages. For comparisons 
between men and women, Pearson chi-
square test for qualitative variables, 
and the two-sample t-test were used. 
Bonferroni adjustment for multiple 
comparisons lead to a p-value <0.002 
considered statistically significant. 
Analyses were performed using Stata 
12 statistical software (Stata Corpora-
tion, College Station,TX).
Results
The study sample comprised 1,027 pa-
tients (early group), almost 90% Cau-
casian, with mean disease duration, 
from the first non-Raynaud symptom, 
of 18 months, 80% were women, and 
40% presented dcSSc. A subgroup of 
S-70 Clinical and Experimental Rheumatology 2018
Gender differences in SSc / P.E. Carreira et al.
461 patients with disease duration of 
less than 12 months (very early group) 
was also analysed. In the very early 
subgroup, 78% were women and 34% 
presented dcSSc. Patient’s characteris-
tics and bivariate associations between 
sex and clinical and demographic char-
acteristics of the early and very early 
groups, are presented in Table I.
In the early group, men, compared to 
women, presented higher mRSS score 
(16 vs. 11), and more frequently dcSSc 
subset (61% vs. 35%), anti-Scl70 anti-
bodies (53% vs. 31%), active disease 
(59% vs. 38%), elevated acute phase 
reactants (56% vs. 32%), CK elevation 
(26% vs. 11%), tendon friction rubs 
(23% vs. 13%), pulmonary fibrosis 
(44% vs. 29%), FVC<80% (39% vs. 
26%) and cardiac conduction blocks 
(9% vs. 7%). On the other hand, wom-
en presented lcSSc and ACA positivity 
more frequently than men. In the very 
early group, the results were similar: 
men, compared to women, presented 
higher mRSS, more aScl70 and less 
ACA, more active disease and acute 
phase reactant elevation, and more fre-
quent organ involvement, specifically 
FVC<80%.
In the analysis stratified by SSc sub-
sets, as shown in Table II, in the early 
group there were no significant differ-
ences related to sex in demographic 
and clinical characteristics in the dc-
SSc subset, except for more elevated 
acute phase response, and a trend to-
wards more aScl70 and CK elevation. 
However, in the lcSSc subset, men 
had higher mRSS (8 vs. 6), more fre-
quently elevated acute phase reactants 
(45% vs. 25%) and cardiac conduction 
blocks (18% vs. 5%), and less ACA 
(21% vs. 51%) than women. Although 
no other differences showed statistical 
significance within the lcSSc subset, 
we found a marked trend towards more 
frequent active disease, joint contrac-
tures, CK elevation, FVC<80% and 
pulmonary fibrosis in men compared to 
women.
Table I. Baseline characteristics and bivariate associations between sex and clinical and demographic characteristics in early (less than 3 
years from the first non-Raynaud symptom) and very early (less than 1 year from the first non-Raynaud symptom) groups.
Variable Very early disease (≤1 year) Early disease (≤ 3 years)§
 n=461 n=1027
 Men Women p-value* Men Women p-value*
 (n=100) (n=361)  (n=200) (n=827) 
Quantitative variables, mean±SD (n)
Age (yr)
   • At 1st non-Raynaud’s symptom 50.9±13.7 (100) 49.6±14.7 (361) 0.414 50.0±14.9 (200) 50.4±14.5 (827) 0.730
   • At 1st SSc symptom 48.3±1.4 (100) 46.4±0.8 (361) 0.271 47.5±1.0 (200) 46.9±0.5 (827) 0.603
   • At 1st EUSTAR entry  52.1±13.6 (100) 50.8±14.7 (361) 0.458 51.6±14.9 (200) 52.2±14.6 (827) 0.589
Disease duration (m)† 11.9±0,7 (100) 11.8±0.9 (413) 0.695 18.0±6.2 (200) 18.6±6.2 (827) 0.198
Raynaud – non-Raynaud (m)  31.2±66 (100) 38.4±84 (361) 0.390 28.8±68.4 (200) 40.8±86.4 (827) 0.031
mRSS 14.8±9.6 (99) 10.5±9.4 (352) 0.0001 16.0±10.5 (199) 10.8±9.8 (816) <0.0001
DLCO (% of predicted) 62.8±23.8 (78) 73.3±18.8 (255) 0.0005 66.2±22.3 (155) 72.3±20.0 (585) 0.001
Qualitative variables, n; percentage (n)
Active disease 61; 66% (92) 143; 42% (344) <0.0001 112; 59%  (190) 307; 38% (802) <0.0001
Antibodies 
Scl-70 57; 57% (99) 109; 31% (353) <0.0001 104; 53% (196) 256; 31% (811) <0.0001 
ACA 11; 11% (96) 110; 32% (340) <0.0001 18; 9% (189) 263; 33% (789) <0.0001
SSc subsets
   • dcSSc 59; 60.2% (98) 120; 33.6% (357) <0.0001 120; 61% (197) 286; 35% (818) <0.0001
   • lcSSc 34; 34.7% (98) 202; 56.6% (357) <0.0001 68; 34% (197) 463; 57% (818) <0.0001
Elevated acute phase reactants 60; 61% (98) 121; 34% (351) <0.0001 109; 56% (195) 259; 32% (808) <0.0001
Digital ischaemic ulcers 40; 40% (99) 98; 27% (360) 0.011 73; 37% (199) 233; 28% (825) 0.020
Synovitis 21; 21% (99) 85; 24% (360) 0.616 46; 23% (199) 161; 19% (826) 0.253
Joint contractures (any joint) 35; 36% (98) 95; 26% (359) 0.072 75; 38% (198) 220;27% (825) 0.002
Tendon friction rubs 23; 24% (96) 49; 14% (357) 0.015 46; 23% (196) 110; 13% (820) <0.0001
CK elevation 25; 26% (97) 47; 13% (351) 0.003 55; 26% (195) 92; 11% (807) <0.0001
Digestive tract involvement‡ 64; 65% (99) 236; 66% (359) 0.840 135; 69% (135) 561; 68% (824) 0.947
sPAP> 40 mm Hg on Doppler-echocardiography 25; 26% (97) 57; 16% (348) 0.035 40; 20% (196) 129; 16% (804) 0.144
Pulmonary fibrosis 43; 45% (96) 95; 27% (353) 0.001 86; 44% (194) 232; 29% (810) <0.0001
FVC<80% of predicted 40; 41% (98) 70; 20% (347) <0.0001 77; 39% (196) 208; 26% (803) <0.0001
Cardiac conduction blocks 16; 16% (98) 26;  7% (348) 0.008 89; 9% (196) 60;  7% (806) 0.001
LV diastolic dysfunction 22; 23% (97) 48; 14% (348) 0.034 35; 18% (196) 116; 14% (805) 0.227
LV ejection fraction<55% 5; 5% (98) 14; 4% (346) 0.648 10; 5% (197) 34; 4% (799) 0.616
Renal crisis  6; 6% (98) 11; 3% (360) 0.155 8; 4% (198) 26; 3% (826) 0.529
Yr: year; m: month; mRSS: modified Rodnan skin score; DLCO: diffusion capacity of the lung for carbon monoxide; ACA: anticentromere autoantibody; 
CK: creatin kinase; sPAP: estimated systolic pulmonary artery pressure; FVC: forced vital capacity; LV: left ventricle; SD: standard deviation.
§Early group (≤3 years) includes the patients from the very early group (≤1 year). *Bonferroni adjustment was used for multiple comparisons. A p-value 
<0.002 was considered statistically significant. †Disease duration was calculated on the basis of the onset of the first SSc symptom, including Raynaud’s 
phenomenon. ‡Digestive tract involvement includes oesophagus, stomach and gut symptoms.
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From the total sample, 650 patients had 
a disease duration of less than 3 years 
from the first SSc symptom, including 
Raynaud’s phenomenon (77%women, 
mean disease duration 17±10 months). 
The results of the analysis of this 
group, including the very early sub-
group, with less than one year from the 
first SSc symptom, including Raynaud 
(204 patients, 74% women, mean dis-
ease duration 7±5 months) were very 
similar to the results found in the whole 
sample (Table III). In the analysis strat-
ified by SSc subsets (Table IV), in the 
dcSSc group, men presented more fre-
quently anti-Scl70 and elevated acute 
phase reactants than women. There 
were not statistical differences between 
men and women in the lcSSc subgroup, 
but there was a trend towards a higher 
mRSS, more active disease and elevat-
ed acute phase reactants, CK elevation, 
FVC>80% of predicted and cardiac 
conduction blocks in men compared to 
women.
Discussion
Although male sex has been associated 
with worse disease outcomes in SSc, to 
our knowledge, no studies have prop-
erly examined sex differences in clini-
cal expression at early stages of the 
disease. 
In the initial reports of the EUSTAR co-
hort, the only sex differences identified 
were basically that men, compared to 
women, were younger at disease onset, 
presented a shorter time between the 
onset of Raynaud’s phenomenon and 
the first non-Raynaud’s symptom and 
had less ACA positivity than women 
(18, 23). In a recent study analysing the 
effect of sex on disease phenotype and 
outcome in the EUSTAR cohort, in-
cluding more than 9,000 patients, male 
sex was associated with more severe 
disease at baseline, showing more dc-
SSc subset, digital ulcers, and pre-cap-
illary pulmonary hypertension and was 
also predictive of new development of 
pre-capillary pulmonary hypertension 
and heart dysfunction (22). However, 
in this study, patients mean disease du-
ration was 8.5 years from the first non-
Raynaud symptom, a prevalent cohort, 
where most patients had already devel-
oped the full clinical picture. 
Our study shows that men present a 
more severe disease than women from 
very early stages of the disease. Men 
Table II. Bivariate associations between sex and clinical and demographic characteristics, according to disease subset, in patients with 
disease duration of less than 3 years from the first non-Raynaud symptom.
Variable dcSSc n=406 (43%)§ lcSSc n=531 (57%)§ 
 Men Women p-value* Men Women p-value*
 (n=120) (n=286)  (n=68) (n=463) 
Quantitative variables: mean±SD (N)
Age (yr)
• At 1st non-Raynaud symptom 48.0±13.8  120) 48.6±14.8 (286) 0.711 53.8±15.6 (68) 51.9±14.0 (463) 0.293
• At 1stSSc symptom 46.3±1.2 (120) 46.9±0.9 (286) 0.711 50.1±2.0 (68) 47.1±0.7 (463) 0.125
• At 1st EUSTAR entry 49.7±13.8 (120) 50.5±14.8 (286) 0.620 55.4±15.6 (77) 53.8±14.1 (463) 0.384
Disease duration (m)† 18.1±6.3 (120) 18.8±6.1 (286) 0.322 17.8±6.2 (68) 18.6±6.2 (463) 0.369
Raynaud – non-Raynaud (m)  19.2±55.2 (120) 18±60 (286) 0.905 43.2±85.2 (68) 57.6±99.6 (463) 0.297
mRSS 21.2±9.9 (120) 20.2±9.4 (280) 0.336 8.2±4.5 (68) 6.2±5.1 (459) 0.002
DLCO (% of predicted) 65.5±20.9 (89) 66.2±20.6 (184) 0.775 67.4±25.1 (57) 74.9±18.5 (315) 0.036
Qualitative variables:  n; percentage (N)
Active disease 84; 73% (115) 188; 67% (280) 0.250 23; 36% (63) 105; 23% (448) 0.025
Antibodies 
• Scl-70 78;  67% (116) 141; 51% (278) 0.003 22; 32% (68) 97; 21% (455)  0.043
• ACA  3;3% (112) 14; 5% (263) 0.260 14; 21% (66) 228 ; 51% (450) <0.0001
Elevated acute phase reactants 73; 62% (117) 125; 45% (275) 0.002 30; 45% (66) 114; 25% (457) <0.0001
Digital Ischaemiculcers 47; 39% (120) 95; 33% (286) 0.251 22; 32% (68) 125; 27% (461) 0.368
Synovitis 29; 24% (120) 65;  24% (286) 0.754 15; 22% (68) 78; 17% (462) 0.295
Joint contractures (any joint) 52; 44% (119) 131; 46% (286) 0.698 19; 28% (68) 79; 17% (513) 0.032
Tendon friction rubs 39; 33% (118) 74; 26% (283) 0.161 6; 9% (68) 27; 6% (459) 0.350
CK elevation 34; 29% (116) 46; 17% (274) 0.005 12; 18% (68) 32; 7% (457) 0.003
Digestive tract involvement‡ 78; 65% (120) 218; 76% (286) 0.020 51; 75% (68) 301; 65% (460) 0.118
sPAP> 40 mm Hg on Doppler-echocardiography 32; 23% (137) 63; 19% (332) 0.283 11; 16% (67) 71; 16% (451) 0.888
Pulmonary fibrosis 59; 50% (117) 116; 41% (279) 0.106 24; 35% (68) 100; 22% (457) 0.015
FVC<80% of predicted 49; 42% (117) 107; 39% (275) 0.582 23;  34% (68) 89; 20% (454) 0.008
Cardiac conduction blocks 17; 14% (117) 28; 10% (280) 0.194 14; 18% (68) 25;5% (452) <0.0001
LV diastolic dysfunction 23; 19% (119) 47; 17% (279) 0.552 10; 15% (67) 59; 13% (451) 0.679
LV ejection fraction<55% 7; 6% (119) 11; 4% (274) 0.416 3; 4% (68) 18; 4% (451) 0.870
Renal crisis  6; 5% (120) 19; 7% (285) 0.525 2; 3% (68) 6;  1% (463) 0.298
dcSSc: diffuse cutaneous systemic sclerosis; lcSSc: limited cutaneous systemic sclerosis; yr: year; m: month; mRSS: modified Rodnan skin score; DLCO: 
diffusion capacity of the lung for carbon monoxide; ACA: anticentromere autoantibody; CK: creatin kinase; sPAP: estimated systolic pulmonary artery pres-
sure; FVC: forced vital capacity; LV: left ventricle; SD: standard deviation.
§From 1,027 patients in the early group, only 937 had information regarding disease subset. *Bonferroni adjustment was used for multiple comparisons. 
A p-value <0.002 was considered statistically significant. †Disease duration was calculated on the basis of the onset of the first non-Raynaud’s symptom. 
‡Digestive tract involvement includes oesophagus, stomach and gut symptoms.
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showed more frequently active disease, 
dcSSc subset, anti-Scl-70 antibodies, 
elevated acute phase reactants, mus-
cular and pulmonary involvement. The 
most interesting finding of the present 
study is that men with early lcSSc pre-
sent a clinical picture suggestive of a 
more severe disease than women, with 
increased organ involvement, similar 
to that observed in dcSSc patients. In 
contrast, men and women with early 
dcSSc presented similar disease se-
verity. Although less evident and not 
statistically significant, probably due 
to the lower number of patients in this 
subgroup, even in patients with very 
early disease (less than one year from 
the first non-Raynaud symptom), sex 
differences were still apparent (Table 
I). It is possible that at least some of 
these early lcSSc patients have not 
developed yet the full disease expres-
sion at the moment of EUSTAR entry, 
and could become dcSSc soon after 
inclusion. In this regard, our results 
would suggest that some men with 
early lcSSc, but showing some fea-
tures of dcSSc, should be managed as 
dcSSc patients with very close clinical 
monitoring, in order to detect as early 
as possible any kind of organ involve-
ment. Another explanation to our find-
ings could be, as it has been suggested, 
that men with less severe and indolent 
disease course might not demand med-
ical care for milder features, whereas 
women may consult more often for 
non-specific symptoms (15). This may 
account, at least in part, for the high 
rate of severe cases in the group of 
men with limited disease subset. It is 
known that mRSS may decline spon-
taneously even in patients with very 
early disease (25), so it would be pos-
sible that some of the lcSSc patients 
could have a dcSSc whose skin disease 
has regressed to an lcSSc distribution 
at EUSTAR enrolment. However, this 
seems not to be the cause, because in 
EUSTAR, by definition, patients with 
dcSSc involvement at any time during 
Table III. Bivariate associations between sex and clinical and demographic characteristics, according to disease duration at first EUSTAR 
entry, from thefirst SSc symptom, including Raynaud’s phenomenon.
Variable Very early disease (≤1 year) n=204 Early disease (≤ 3 years)§ n=650 
 Men Women p-value* Men Women p-value*
 (n=53) (n=151)  (n=149) (n=501) 
Quantitative variables, mean±SD (n)
Age (yr)
• At 1st non-Raynaud’s event 50.5±15.3 (53) 50.0±13.9 (151) 0.830 49.0±15.0 (149) 49.5±14.5 (501) 0.726 
• At 1st Raynaud event  50.5±15.2 (53) 50.1±13.9 (151) 0.855 48.8±15.0 (149) 49.2±14.6 (501) 0.764
• At 1st EUSTAR entry  51.7±15.3 (53) 51.2±13.8 (151) 0.832 50.6±15.0 (149) 51.2±14.6 (501) 0.706
Disease duration (m)† 5.88±5.88 (53) 6.6±4.68 (151) 0.416 16.9±10.3 (149) 18.0±9.6 (501) 0.226
Raynaud – non-Raynaud (m)  -0.6±6.0 (53) -1.7±6.0 (151) 0.328 3.0±7.1 (149) 3.5±8.6 (501) 0.507
mRSS 18.4±10.1 (53) 13.0±10.1 (151) 0.0008 17.0±10.5 (149) 12.7±10.3 (502) <0.0001
DLCO (% of predicted) 63.6±23.3 (41) 70.7±18.2 (96) 0.058 66.9±21.0 (117) 71.5±19.2 (332) 0.033
Qualitative variables, n; percentage (n)
Active disease 35; 74% (47) 77; 53% (144) 0.011 89; 63% (142) 212; 44% (483) <0.0001
Antibodies
• Scl-70 36; 70% (51) 42; 29% (147) <0.0001 78; 54% (145) 176; 36% (489)  <0.0001
• ACA 2; 4% (51) 25; 18% (141) 0.015 10; 7% (141) 105; 22% (471) <0.0001
SSc subsets
• dcSSc 39; 73.6% (53) 75; 50.0% (150) 0.003 97; 66% (147) 220; 44% (495) <0.0001
• lcSSc 13; 24.5% (53) 59; 39.3% (150) 0.053 44; 30% (147) 237; 49% (495) <0.0001
Elevated acute phase reactants 34; 65% (52) 53; 36% (146) <0.0001 82; 56% (146) 165; 34% (487) <0.0001
Digital ischaemic ulcers 19; 36% (53) 39; 26% (151) 0.164 54; 36% (149) 125; 25% (500) 0.007
Synovitis 14; 26% (53) 40; 26% (151) 0.992 33; 22% (149) 96; 19% (500) 0.429
Joint contractures (any joint) 20; 38% (53) 51; 34% (151) 0.602 58; 39% (148) 156; 31% (500) 0.069
Tendon friction rubs 15; 29% (52) 28; 18% (151) 0.117 36; 24% (147) 79; 16% (497) 0.017
CK elevation 15; 29% (52) 24; 16% (146) 0.053 42; 29% (145) 67; 14% (491) <0.0001
Digestive tract involvement‡ 37;70% (53) 99; 66% (151) 0.572 102; 68% (149) 333; 67% (500) 0.672
sPAP> 40 mm Hg on Doppler-echocardiography 9; 17% (52) 29; 20% (144) 0.658 25; 17% (147) 79; 16% (485) 0.837
Pulmonary fibrosis 21; 40% (52) 46; 31% (147) 0.233 60; 41% (146) 155; 31% (489) 0.028
FVC<80% of predicted 16; 31% (52) 35; 24% (144) 0.363 60; 41% (147) 130; 27% (487) 0.001
Cardiac conduction blocks 11; 21% (52) 12; 8% (144) 0.014 19; 13% (146) 37; 8% (486) 0.044
LV diastolic dysfunction 19; 21% (52) 19; 13% (143) 0.178 27; 18% (146) 75; 15% (487) 0.340
LV ejection fraction<55% 4; 8% (52) 5; 3% (142) 0.221 8; 5% (147) 19; 4% (480) 0.438
Renal crisis  2; 4% (53) 4; 3% (150) 0.683 7; 5% (149) 18; 4% (500) 0.541
SSc: systemic sclerosis; yr: year; mRSS: modified Rodnan skin score; DLCO: diffusion capacity of the lung for carbon monoxide; ACA: anticentromere 
autoantibody; dcSSc: diffuse cutaneous systemic sclerosis; lcSSc: limited cutaneous systemic sclerosis; CK: creatin kinase; sPAP: estimated systolic pulmo-
nary artery pressure; FVC: forced vital capacity; LV: left ventricle; SD: standard deviation.
§Early group (≤ 3 years) includes the patients from the very early group (≤1 year). *Bonferroni adjustment was used for multiple comparisons. A p-value 
<0.002 was considered statistically significant. †Disease duration was calculated on the basis of the onset of the first SSc symptom, including Raynaud’s 
phenomenon.  ‡Digestive tract involvement includes oesophagus, stomach and gut symptoms.
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disease course have to be considered 
always dcSSc. Nevertheless, to dis-
card this possibility we analysed the 
group of patients with less than 3 years 
from the first SSc symptom, includ-
ing Raynaud’s phenomenon, with very 
similar results both in the early, very 
early and lcSSc subgroups, although 
with less statistical power, probably 
due to the smaller number of patients 
analysed. 
The main strength of the present study 
is the large number of patients included 
in the early EUSTAR database. This al-
lowed us to assess sex differences even 
across population subgroups as those 
with very early disease or the SSc sub-
sets. Therefore, we are confident that 
the study sample is representative and 
our results robust and reliable.
Our study has also some limitations. 
First, while nowadays there is exter-
nal monitoring done for a selection of 
patients, at the time of the data export 
for the present study, external monitor-
ing was not part of the EUSTAR proce-
dures. Then, although it is supposed that 
in each participating centre, all patients 
with SSc are incorporated into the EU-
STAR database, there could be a bias 
towards the inclusion of more severe 
cases. If this is true, this should be both 
for men and women, then no affecting 
the results. Second, since the new 2013 
ACR/EULAR classification criteria 
for SSc (24) were not available in this 
early database, only patients fulfilling 
the 1980 ACR criteria for the classifi-
cation of SSc (20) were selected, and it 
is well known that these exclude up to 
20% of lcSSc patients, and there could 
be patients not fulfilling SSc ACR 1980 
classification criteria with severe viscer-
al involvement (25, 26). Nevertheless, 
these cases are scarce (27). Third, serum 
autoantibodies have been performed in 
a large number of laboratories, without 
standardisation. However, only ACA 
and anti-Scl70 antibodies are analysed 
in our study, and both antibodies have 
shown good agreement between differ-
ent methods (indirect immunofluores-
cence and multiplex) (28). Other limi-
tation could be the lack of data regard-
ing to smoking status in our patients. 
Finally, most EUSTAR patients come 
from European countries and the vast 
majority is therefore Caucasian. As a 
result, our findings should be carefully 
extrapolated to other ethnic groups (28).
Table IV. Bivariate associations between sex and clinical and demographic characteristics, according to disease subset, in patients with 
disease duration of less than 3 years from the first SSc symptom, including Raynaud’s phenomenon.
 dcSSc (N=317)§ lcSSc (N=281)§
Variable Men Women p-value* Men Women p-value*
 (n=97) (n=220)  (n=44) (n=237) 
Quantitative variables, mean±SD (n)
Age (yr)
• At 1stnon-Raynaud’s event 47.5±13.8 (97) 48.3±14.6 (220) 0.613 53.7±16.1 (44) 50.7±14.3 (237) 0.206 
• At 1st Raynaud event 47.2±13.8 (97) 48.1±14.7 (220) 0.610 53.4±16.2 (44) 50.3±14.3 (237) 0.195
• At 1st EUSTAR entry  49.1±13.8 (97) 50.1±14.6 (220) 0.566 55.4±16.0 (44) 52.4±14.4 (237) 0.319
Disease duration (m)†  16.8±10.8 (97) 16.8±9.6 (220) 0.706 18.0±10.8 (44) 19.2±9.6 (237) 0.312
Raynaud – non-Raynaud (m)  2.4±6.96 (97) 2.04±8.16 (220) 0.753 4.08±7.56 (44) 4.92±9.12 (237) 0.543
mRSS 21.2±10.0 (97) 20.7±9.1 (219) 0.653 8.9±4.9 (44) 6.6±5.5 (237) 0.010
DLCO (% of predicted)  66.9±20.1 (76) 67.0±20.2 (144) 0.975 67.3±23.8 (35) 74.5±17.4 (155) 0.102
Qualitative variables, n; percentage (n)
Active disease 66; 71% (93) 146; 68% (215) 0.594 19;46% (41) 56; 25% (26) 0.005
Antibodies
• Scl-70 63; 68% (93) 104; 49% (214) 0.002 13;30% (44)  63; 27% (231) 0.757
• ACA 2; 2% (90) 6; 3% (201) 0.713 8;18% (44) 91; 40% (227) 0.006
Elevated acute phase reactants  59; 63% (94) 92; 43% (212) 0.002 18;41% (44) 62; 27% (232) 0.060
Digital ischaemic ulcers 35; 36% (97) 63; 29% (220) 0.186 16; 36% (44) 54;23% (236) 0.058
Synovitis 22; 23% (97) 50; 21% (220) 0.993 9; 20% (44) 39; 16% (236) 0.526
Joint contractures (any joint) 42; 44% (96) 102; 46% (220) 0.635 12; 27% (44) 47; 20% (236) 0.272
Tendon friction rubs 31; 33% (95) 60; 27% (218) 0.360 4; 9% (44) 13; 5% (235) 0.365
CK elevation  29; 31% (93) 36; 17% (214) 0.005 9; 20% (44) 21; 9% (234) 0.024
Digestive tract involvement‡ 64; 66% (97) 166; 75% (220) 0.081 33; 75% (44) 144; 61% (236) 0.077
sPAP> 40 mm Hg on Doppler-echocardiography 18; 19% (96) 38; 17% (218) 0.779 7; 16% (44) 39; 17% (229) 0.856
Pulmonary fibrosis  44; 46% (95) 87; 40% (216) 0.321 14; 32% (44) 56; 24% (232) 0.283
FVC<80% of predicted 38; 40% (95) 76; 36% (213) 0.468 18; 41% (44) 49; 21% (233) 0.005
Cardiac conduction blocks  11; 12% (94) 21; 10% (216) 0.598 8; 18% (44) 12; 5% (229) 0.003
LV diastolic dysfunction  19; 20% (96) 37; 17% (214) 0.597 6; 14% (43) 31; 13% (231) 0.925
LV ejection fraction<55%  5; 5% (96) 9; 4% (212) 0.707 3; 7% (44) 5; 2% (227) 0.098
Renal crisis  6; 6% (97) 15; 7% (219) 0.827 1; 2% (44) 2; 1% (237) 0.397
SSc: systemic sclerosis; dcSSC: diffuse cutaneous systemic sclerosis; lcSSc: limited cutaneous systemic sclerosis; yr: year; m: months; mRSS: modified 
Rodnan skin score; DLCO: diffusion capacity of the lung for carbon monoxide; ACA: anticentromere autoantibody; CK: creatinkinase; sPAP: stimated 
systolic pulmonary artery pressure; FVC: forced vital capacity; LV: left ventricle; SD: standard deviation.
§From 650 patients in the group, only 598 had information regarding disease subset. *Bonferroni adjustment was used for multiple comparisons. A p-value 
<0.002 was considered statistically significant. †Disease duration was calculated on the basis of the onset of the first SSc symptom, including Raynaud’s 
phenomenon. ‡Digestive tract involvement includes esophagus, stomach and gut symptoms.
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In conclusion, our results show that 
there is a different clinical pattern ac-
cording to sex in patients with early 
onset SSc. Men, compared to women, 
presented data of more severe disease 
from very early stages of the disease, 
and these differences are much more 
evident in patients with early lcSSc. 
Our findings suggest that men with 
early SSc, even those with the lcSSc 
subset, should be carefully monitored, 
in order to detect visceral involvement 
even in the absence of other clinical 
symptoms. This will help to select the 
best therapeutic strategy for every SSc 
patient
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